{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:26:00Z","timestamp":1787023560336,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is the most common malignancy among women worldwide, and the number of survivors continues to increase owing to earlier detection and advances in treatment. As long-term survivorship becomes increasingly important, minimizing treatment-related toxicity without compromising oncologic outcomes has become a major goal in the management of early breast cancer. Treatment de-escalation strategies have therefore attracted considerable attention. In HER2-positive disease, several approaches have been explored, including reduction of chemotherapy intensity, shortening the duration of anti-HER2 therapy, chemotherapy-free regimens in selected patients, and response-guided strategies based on pathologic complete response following neoadjuvant therapy. In hormone receptor\u2013positive HER2-negative breast cancer, multigene expression assays have enabled more precise risk stratification and have allowed omission of adjuvant chemotherapy in patients with biologically low-risk tumors. In addition, the neoadjuvant setting provides an opportunity to evaluate treatment response using biomarkers such as Ki67, which may help identify patients who can safely avoid chemotherapy. Ongoing clinical trials are further evaluating response-guided treatment strategies, particularly in premenopausal patients. Furthermore, circulating tumor DNA has recently emerged as a promising biomarker for detecting minimal residual disease and monitoring treatment response. Integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches. This review summarizes current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes.<\/jats:p>","DOI":"10.1093\/jjco\/hyag131","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:55:58Z","timestamp":1785412558000},"source":"Crossref","is-referenced-by-count":0,"title":["De-escalation of perioperative systemic therapy for early breast cancer"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-451X","authenticated-orcid":false,"given":"Makiko","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tokyo Women\u2019s Medical University School of Medicine , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgical Oncology, Sagara Hospital , 3-31 Matsubaracho, Kagoshima-shi, Kagoshima 892-0833 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-4972","authenticated-orcid":false,"given":"Toshiyuki","family":"Ishiba","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Institute of Science Tokyo Hospital , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-648X","authenticated-orcid":false,"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , 3-8-31 Ariake, Koto-ku, Tokyo 135-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , 3-8-31 Ariake, Koto-ku, Tokyo 135-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"Hideo","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University Hospital , 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-8170","authenticated-orcid":false,"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security , 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-9428","authenticated-orcid":false,"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Terata","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Akita University Hospital , 44-2 Hasunuma, Hiroomote, Akita-shi 010-8543 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-9064","authenticated-orcid":false,"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Department of Advanced Clinical Research and Development, Nagoya City University, Graduate School of Medical Sciences , 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikata","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Gunma Prefectural Cancer Center , 617-1 Takahayashinishicho, Ota-shi, Gunma 373-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-5512","authenticated-orcid":false,"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Okayama University Hospital , 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081722590136300_ref1","volume-title":"Cancer information service NCC","author":"Cancer Statistics"},{"key":"2026081722590136300_ref2","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/jjco\/hyq122","article-title":"The breast cancer working group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer","volume":"40","author":"Toi","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"2026081722590136300_ref3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.rbmo.2021.12.019","article-title":"Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors","volume":"44","author":"Mangiardi-Veltin","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2026081722590136300_ref4","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","article-title":"Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer","volume":"24","author":"Walshe","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref5","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/pon.3268","article-title":"Quantitative assessment of appearance changes and related distress in cancer patients","volume":"22","author":"Nozawa","year":"2013","journal-title":"Psychooncology."},{"key":"2026081722590136300_ref6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/14740338.2022.2151584","article-title":"Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects","volume":"21","author":"Di Nardo","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2026081722590136300_ref7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref8","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.annonc.2020.08.2106","article-title":"A Food and Drug Administration analysis of survival outcomes comparing the adjuvant paclitaxel and trastuzumab trial with an external control from historical clinical trials","volume":"31","author":"Amiri-Kordestani","year":"2020","journal-title":"Ann Oncol"},{"key":"2026081722590136300_ref9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026081722590136300_ref10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026081722590136300_ref12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"key":"2026081722590136300_ref13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026081722590136300_ref14","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet."},{"key":"2026081722590136300_ref15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized short-HER studydouble dagger","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"2026081722590136300_ref16","doi-asserted-by":"publisher","first-page":"e000810","DOI":"10.1136\/bmjonc-2025-000810","article-title":"Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data","volume":"4","author":"Earl","year":"2025","journal-title":"BMJ Oncol"},{"key":"2026081722590136300_ref17","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","article-title":"Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients","volume":"38","author":"Sawaki","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet."},{"key":"2026081722590136300_ref19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s10147-026-02967-7","article-title":"Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial","volume":"31","author":"Shigematsu","year":"2026","journal-title":"Int J Clin Oncol"},{"key":"2026081722590136300_ref21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026081722590136300_ref23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaoncol.2023.0646","article-title":"Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive\/ERBB2-positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial","volume":"9","author":"Gluz","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026081722590136300_ref24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2217\/fon-2022-1282","article-title":"DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer","volume":"19","author":"Debien","year":"2023","journal-title":"Future Oncol"},{"key":"2026081722590136300_ref26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","author":"Early Breast Cancer Trialists' Collaborative Group. Electronic address bocoau, Early Breast Cancer Trialists' Collaborative G","year":"2023","journal-title":"Lancet."},{"key":"2026081722590136300_ref27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref28","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref29","doi-asserted-by":"publisher","first-page":"PS5-07-04","DOI":"10.1158\/1557-3265.SABCS25-PS5-07-04","article-title":"Abstract PS5-07-04: NRG-BR009: a phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression\u00a0+\u00a0endocrine therapy in premenopausal women with pN0-1, HR+\/HER2- breast cancer and recurrence score \u226425 (OFSET)","volume":"32","author":"Swain","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026081722590136300_ref30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026081722590136300_ref32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref33","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref34","doi-asserted-by":"publisher","first-page":"PS5-07-10","DOI":"10.1158\/1557-3265.SABCS25-PS5-07-10","article-title":"Abstract PS5-07-10: young HOPE\/JCOG2402: a randomized phase III study of response-guided therapy following neoadjuvant endocrine therapy to optimize adjuvant treatment in premenopausal HR+\/HER2- breast cancer","volume":"32","author":"Ono","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026081722590136300_ref35","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1200\/JCO.2024.42.16_suppl.518","article-title":"ctDNA monitoring for breast cancer at high risk of recurrence: interim analysis of JCOG1204A1","volume":"42","author":"Naito","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081722590136300_ref36","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jjco\/hyaf113","article-title":"Current status and perspective of ctDNA-based MRD testing in breast cancer: a systematic review","volume":"55","author":"Ozaki","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026081722590136300_ref37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref38","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026081722590136300_ref39","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"key":"2026081722590136300_ref40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","article-title":"De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+\/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"23","author":"Nitz","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag131\/70672598\/hyag131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag131\/70672598\/hyag131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:59:09Z","timestamp":1787021949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag131\/8762912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag131","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"hyag131"}}